Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
2.
Clin Orthop Relat Res ; 466(6): 1492-8, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18338216

RESUMEN

Bone cements loaded with combinations of antibiotics are assumed more effective in preventing infection than bone cements with gentamicin as a single drug. Moreover, loading with an additional antibiotic may increase interconnectivity between antibiotic particles to enhance release. We hypothesize addition of clindamycin to a gentamicin-loaded cement yields higher antibiotic release and causes larger inhibition zones against clinical isolates grown on agar and stronger biofilm inhibition. Antibiotic release after 672 hours from Copal bone cement was more extensive (65% of the clindamycin and 41% of the gentamicin incorporated) than from Palacos R-G (4% of the gentamicin incorporated). The higher antibiotic release from Copal resulted in a stronger and more prolonged inhibition of bacterial growth on agar. Bacterial colony counting and confocal laser scanning microscopy of biofilms grown on the bone cements suggest antibiotic release reduced bacterial viability, most notably close to the cement surface. The gentamicin-sensitive Staphylococcus aureus formed gentamicin-resistant small colony variants on Palacos R-G and therefore Copal more effectively decreased biofilm formation than Palacos R-G.


Asunto(s)
Antibacterianos/farmacocinética , Biopelículas , Cementos para Huesos/farmacocinética , Clindamicina/farmacocinética , Gentamicinas/farmacocinética , Polimetil Metacrilato/farmacocinética , Difusión , Solubilidad , Staphylococcus aureus/efectos de los fármacos , Staphylococcus aureus/crecimiento & desarrollo
3.
Eur J Nucl Med Mol Imaging ; 35(4): 798-807, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18183394

RESUMEN

PURPOSE: We hypothesized that assessment of myocardial sympathetic activity with no-carrier-added (nca) (123)I-meta-iodobenzylguanidine (MIBG) compared to carrier-added (ca) (123)I-MIBG would lead to an improvement of clinical performance without major differences in radiation dosimetry. METHODS: In nine healthy volunteers, 15 min and 4 h planar thoracic scintigrams and conjugate whole-body scans were performed up to 48 h following intravenous injection of 185 MBq (123)I-MIBG. The subjects were given both nca and ca (123)I-MIBG. Early heart/mediastinal ratios (H/M), late H/M ratios and myocardial washout were calculated. The fraction of administered activity in ten source organs was quantified from the attenuation-corrected geometric mean counts in conjugate views. Radiation-absorbed doses were estimated with OLINDA/EXM software. RESULTS: Both early and late H/M were higher for nca (123)I-MIBG (ca (123)I-MIBG early H/M 2.46 +/- 0.15 vs nca (123)I-MIBG 2.84 +/- 0.15, p = 0.001 and ca (123)I-MIBG late H/M 2.69 +/- 0.14 vs nca (123)I-MIBG 3.34 +/- 0.18, p = 0.002). Myocardial washout showed a longer retention time for nca (123)I-MIBG (p < 0.001). The effective dose equivalent (adult male model) for nca (123)I-MIBG was similar to that for ca (123)I-MIBG (0.025 +/- 0.002 mSv/MBq vs 0.026 +/- 0.002 mSv/MBq, p = 0.055, respectively). CONCLUSION: No-carrier-added (123)I-MIBG yields a higher relative myocardial uptake and is associated with a higher myocardial retention. This difference between nca (123)I-MIBG and ca (123)I-MIBG in myocardial uptake did not result in major differences in estimated absorbed doses. Therefore, nca (123)I-MIBG is to be preferred over ca (123)I-MIBG for the assessment of cardiac sympathetic activity.


Asunto(s)
3-Yodobencilguanidina/farmacocinética , Sistema de Conducción Cardíaco , Radioisótopos de Yodo/farmacocinética , Sistema Nervioso Simpático/diagnóstico por imagen , 3-Yodobencilguanidina/administración & dosificación , Femenino , Corazón/diagnóstico por imagen , Humanos , Inyecciones , Radioisótopos de Yodo/administración & dosificación , Cinética , Masculino , Cintigrafía , Valores de Referencia , Distribución Tisular , Irradiación Corporal Total/métodos
4.
J Antimicrob Chemother ; 58(6): 1287-90, 2006 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17041238

RESUMEN

OBJECTIVES: Antibiotic-loaded bone cements are used for the permanent fixation of joint prostheses. Antibiotic-loaded cements significantly decrease the incidence of infection. The objective of this study was to investigate whether the viability of bacteria derived from patients with a prosthesis-related infection could be further decreased when antibiotic release from bone cements was combined with application of pulsed ultrasound. METHODS: Escherichia coli ATCC 10798, Staphylococcus aureus 7323, coagulase-negative staphylococci (CoNS 7368 and CoNS 7391) and Pseudomonas aeruginosa 5148 were grown planktonically in suspension and as a biofilm on three different bone cements: Palacos R without gentamicin as control, gentamicin-loaded Palacos R-G and gentamicin/clindamycin-loaded Copal. The viability of planktonic and biofilm bacteria was measured in the absence and presence of pulsed ultrasound for 40 h. RESULTS: Ultrasound itself did not affect bacterial viability. However, application of pulsed ultrasound in combination with antibiotic release by antibiotic-loaded bone cements yielded a reduction of both planktonic and biofilm bacterial viability compared with antibiotic release without application of ultrasound. CONCLUSIONS: This study shows that antibiotic release in combination with ultrasound increases the antimicrobial efficacy further than antibiotic release alone against a variety of clinical isolates. Application of ultrasound in combination with antibiotic release in clinical practice could therefore lead to better prevention or treatment of prosthesis-related infections.


Asunto(s)
Antibacterianos/metabolismo , Antibacterianos/farmacología , Bacterias/efectos de los fármacos , Biopelículas/crecimiento & desarrollo , Cementos para Huesos/química , Viabilidad Microbiana , Ultrasonido , Biopelículas/efectos de los fármacos , Clindamicina/farmacología , Recuento de Colonia Microbiana , Gentamicinas/farmacología
5.
J Biomed Mater Res B Appl Biomater ; 75(1): 1-5, 2005 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16044459

RESUMEN

Gentamicin-loaded acrylic beads are loosely placed in infected bone cavities, whereas gentamicin-loaded acrylic bone cement is used as a mechanical filler in bone to anchor prosthetic components. Both drug delivery systems are used to decrease infection rates by gentamicin release. The objective of this study is to investigate the effects of pulsed ultrasound on gentamicin release from both materials. Gentamicin release from gentamicin-loaded beads (Septopal) and from three commercially-available brands of gentamicin-loaded bone cement (CMW 1, Palacos R-G, and Palamed G) was measured after 18 h of exposure in PBS to an ultrasonic field of 46.5 kHz in a 1:3 duty cycle with an average acoustic intensity of 167 mW/cm(2). Samples not exposed to ultrasound were used as controls. Pulsed ultrasound significantly enhanced gentamicin release from gentamicin-loaded beads, whereas gentamicin release from the gentamicin-loaded bone cements was not significantly enhanced. Mercury intrusion porosimetry revealed an increased distribution of pores between 0.1 and 0.01 microm in beads after gentamicin release, while in bone cements no increase in the number of pores was found. Increased gentamicin release in beads due to ultrasound may be explained by micro-streaming in a porous structure, whereas the absence of changes in pore structure after gentamicin release in bone cement is concurrent with the lack of an enhanced release of the antibiotic by ultrasound. As an effective treatment of infections requires high local concentrations of antibiotic, increased gentamicin release due to ultrasound may be of clinical significance, especially since ultrasound has been demonstrated to increase bacterial killing by antibiotics.


Asunto(s)
Antibacterianos/química , Antibacterianos/farmacocinética , Gentamicinas/química , Gentamicinas/farmacocinética , Polimetil Metacrilato/química , Ultrasonido
6.
J Control Release ; 92(3): 369-74, 2003 Oct 30.
Artículo en Inglés | MEDLINE | ID: mdl-14568417

RESUMEN

The release profile of antibiotics from antibiotic-loaded bone cement, used to prevent infections in total joint arthroplasty, is neither ideal nor complete. Ultrasound has been used to allow drugs to cross otherwise impermeable barriers. The aim of this study was to establish a possible effect of ultrasound on antibiotic release from bone cements. Samples were made of three commercially available gentamicin-loaded bone cements. Part of the samples was allowed to release gentamicin for 3 weeks before insonation. An insonation device produced an ultrasound field with a time average acoustic intensity of 167 mW/cm2 at a frequency of 46.5 kHz. The samples were exposed to the ultrasound field or not exposed to it as a control. The amount of gentamicin released was measured by fluorescence polarization immunoassay. There was a limited increase of gentamicin release with application of ultrasound in fresh samples but not in the samples that had been allowed to release gentamicin. For fresh samples, a linear regression model showed that this ultrasound effect was statistically significant. The mechanism behind these observations is not clear, but it is suggested that microstreaming or localized temperature rises may be involved.


Asunto(s)
Sistemas de Liberación de Medicamentos/métodos , Gentamicinas/farmacocinética , Polimetil Metacrilato/metabolismo , Ultrasonido , Preparaciones de Acción Retardada , Sistemas de Liberación de Medicamentos/instrumentación , Gentamicinas/administración & dosificación , Modelos Lineales , Ensayo de Materiales
7.
Semin Nucl Med ; 32(2): 110-22, 2002 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11965606

RESUMEN

Fifty patients with somatostatin receptor-positive tumors were treated with multiple doses of [(111)In-diethylenetriamine pentaacetic acid(0)]octreotide. Forty patients were evaluable after cumulative doses of at least 20 GBq up to 160 GBq. Therapeutic effects were seen in 21 patients: partial remission in 1 patient, minor remissions in 6 patients, and stabilization of previously progressive tumors in 14 patients. Our results thus underscore the therapeutic potential of Auger-emitting radiolabelled peptides. The toxicity was generally mild bone marrow toxicity, but 3 of the 6 patients who received more than 100 GBq developed a myelodysplastic syndrome or leukemia. Therefore, we consider 100 GBq as the maximal tolerable dose. With a renal radiation dose of 0.45 mGy/MBq (based on previous studies) a cumulative dose of 100 GBq [(111)In-DTPA(0)]octreotide will lead to 45Gy on the kidneys, twice the accepted limit for external beam radiation. However, no development of hypertension, proteinuria, or significant changes in serum creatinine or creatinine clearance were observed in our patients including 2 patients who received 106 and 113 GBq [(111)In-DTPA(0)]octreotide without protection with amino acids, over a follow-up period of respectively 3 and 2 years. These findings show that the radiation of the short-range (maximal 10 microns) Auger electrons originating from the cells of the proximal tubules is not harmful for the renal function. The decrease in serum inhibin B and concomitant increase of serum FSH levels in men indicate that the spermatogenesis was impaired.


Asunto(s)
Neoplasias/radioterapia , Octreótido/análogos & derivados , Octreótido/uso terapéutico , Ácido Pentético/análogos & derivados , Ácido Pentético/uso terapéutico , Radiofármacos/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias/química , Neoplasias/diagnóstico por imagen , Tumores Neuroendocrinos/diagnóstico por imagen , Tumores Neuroendocrinos/radioterapia , Octreótido/administración & dosificación , Octreótido/efectos adversos , Ácido Pentético/administración & dosificación , Ácido Pentético/efectos adversos , Cintigrafía , Radiofármacos/administración & dosificación , Radiofármacos/efectos adversos , Dosificación Radioterapéutica , Receptores de Somatostatina/análisis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA